Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives

被引：15

作者：

Citarella, Andrea ^{[1
]}

Dimasi, Alessandro ^{[1
]}

Moi, Davide ^{[2
]}

Passarella, Daniele ^{[1
]}

Scala, Angela ^{[3
]}

Piperno, Anna ^{[3
]}

Micale, Nicola ^{[3
]}

机构：

[1] Univ Milan, Dept Chem, Via Golgi 19, I-20133 Milan, Italy

[2] Univ Cagliari, Dept Chem & Geol Sci, SP 8 CA, I-09042 Cagliari, Italy

[3] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy

来源：

BIOMOLECULES | 2023年 / 13卷 / 09期

关键词：

COVID-19; SARS-CoV-2; M-pro; protease inhibitors; coronavirus; peptidomimetics; Paxlovid; nirmatrelvir; DISCOVERY; DESIGN; SARS; PEPTIDOMIMETICS; KETONES;

D O I：

10.3390/biom13091339

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The main protease (M-pro) plays a pivotal role in the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target. Disruption of the catalytic activity of M-pro produces a detrimental effect on the course of the infection, making this target one of the most attractive for the treatment of COVID-19. The current success of the SARS-CoV-2 M-pro inhibitor Nirmatrelvir, the first oral drug for the treatment of severe forms of COVID-19, has further focused the attention of researchers on this important viral target, making the search for new M-pro inhibitors a thriving and exciting field for the development of antiviral drugs active against SARS-CoV-2 and related coronaviruses.

引用

页数：57

共 50 条

[1] Perspectives on SARS-CoV-2 Main Protease Inhibitors
Gao, Kaifu
Wang, Rui
Chen, Jiahui
Tepe, Jetze J.
Huang, Faqing
Wei, Guo-Wei
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (23) : 16922 - 16955
[2] Multicomponent Synthesis of the SARS-CoV-2 Main Protease Inhibitor Nirmatrelvir
Preschel, H. Daniel
Otte, Ruben T.
Zhuo, Ying
Ruscoe, Rebecca E.
Burke, Ashleigh J.
Kellerhals, Rachel
Horst, Brendan
Hennig, Sven
Janssen, Elwin
Green, Anthony P.
Turner, Nicholas J.
Ruijter, Eelco
[J]. JOURNAL OF ORGANIC CHEMISTRY, 2023, 88 (17): : 12565 - 12571
[3] In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting with the SARS-CoV-2 Main Protease
So, Yuri Alves de Oliveira
Bezerra, Katyanna Sales
Gargano, Ricardo
Mendonca, Fabio L. L.
Souto, Janeusa Trindade
Fulco, Umberto L.
Pereira Jr, Marcelo Lopes
Ribeiro Jr, Luiz Antonio
[J]. BIOMOLECULES, 2024, 14 (07)
[4] Allosteric inhibitors of the main protease of SARS-CoV-2
Samrat, Subodh Kumar
Xu, Jimin
Xie, Xuping
Gianti, Eleonora
Chen, Haiying
Zou, Jing
Pattis, Jason G.
Elokely, Khaled
Lee, Hyun
Li, Zhong
Klein, Michael L.
Shi, Pei-Yong
Zhou, Jia
Li, Hongmin
[J]. ANTIVIRAL RESEARCH, 2022, 205
[5] Developing inhibitors of the SARS-CoV-2 main protease
Seitz, Christian
Markota, Vedran
Sztain-Pedone, Terra
Esler, Morgan
Moghadasi, Arad
Kennelly, Samantha
Demir, Ozlem
Aihara, Hideki
Harki, Daniel A.
Harris, Reuben
McCammon, J. Andrew
Amaro, Rommie E.
[J]. BIOPHYSICAL JOURNAL, 2022, 121 (03) : 192A - 192A
[6] Potential SARS-CoV-2 main protease inhibitors
Banerjee, Riddhidev
Perera, Lalith
Tillekeratne, L. M. Viranga
[J]. DRUG DISCOVERY TODAY, 2021, 26 (03) : 804 - 816
[7] On the origins of SARS-CoV-2 main protease inhibitors
Janin, Yves L.
[J]. RSC MEDICINAL CHEMISTRY, 2024, 15 (01): : 81 - 118
[8] Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
Ullrich, Sven
Ekanayake, Kasuni B.
Otting, Gottfried
Nitsche, Christoph
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 62
[9] Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2
Singh, Desh Deepak
Han, Ihn
Choi, Eun-Ha
Yadav, Dharmendra K.
[J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
[10] Discovery of novel inhibitors of SARS-CoV-2 main protease
Zheng, Lei
Chen, Yanmei
Bao, Jingxiao
He, Liping
Dong, Suzhen
Qi, Yifei
Zhang, John Z. H.
[J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (23): : 12526 - 12534

← 1 2 3 4 5 →